<DOC>
	<DOCNO>NCT01924520</DOCNO>
	<brief_summary>A study evaluate safety plasma concentration change quetiapine repeat administration FK949E ( extended-release formulation quetiapine ) patient major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>Oral Multiple-dose Study Patients With Major Depressive Disorder</brief_title>
	<detailed_description>The objective study evaluate safety pharmacokinetics multiple oral dos FK949E ( extended-release formulation quetiapine ) three dose patient major depressive disorder ( MDD ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosis major depressive disorder M.I.N.I . accord DSMIVTR Female patient childbearing potential negative serum pregnancy test result willing able use reliable method birth control study . Patients could understand comply requirement study , judge investigator/subinvestigator . A current past history DSMIVTR Axis I disorder major depressive disorder within 6 month prior provision write informed consent . Diagnosis DSMIVTR Axis II disorder consider major impact patient 's current psychiatric status . A history substance alcohol abuse dependence exclude caffeine nicotine . Patients unable abstain drug induce inhibit drugmetabolizing enzyme CYP3A4 14 day prior screen assessment throughout study period . Patients show evidence sign renal hepatic failure , serious heart disease , cerebrovascular disease , viral hepatitis B C , acquire immunodeficiency syndrome ( AIDS ) ( carrier ) . Patients treated hypertension patient clinical finding opinion investigator/subinvestigator could negatively affect study would affect study result ( e.g. , hypertension , unstable angina ) . Patients concomitant hypotension orthostatic hypotension ( hypotension define systolic blood pressure le 100 mmHg ) Conditions could affect absorption metabolism study medication ( e.g. , malabsorption syndrome , liver disease ) A current diagnosis malignant tumor unless remission least 5 year ( except basal squamous cell skin carcinoma ) . A history transient ischemic attack ( TIA ) . A history seizure disorder , except febrile convulsion Application electroconvulsive therapy within 90 day prior start study drug administration Use depot antipsychotic injection inability drug period twice dose interval prior screening assessment throughout study period A score â‰¥ 3 HAMD17 Item ( suicide ) suicide attempt within past 6 month . Patients judge serious suicidal homicidal risk opinion investigator/subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antipsychotic</keyword>
	<keyword>FK949E</keyword>
	<keyword>Quetiapine</keyword>
</DOC>